Seres Therapeutics (MCRB) Change in Acquisitions & Divestments (2015 - 2023)

Seres Therapeutics has reported Change in Acquisitions & Divestments for 9 years, with the latest figure at $11.8 million in Q2 2023.

• Quarterly Change in Acquisitions & Divestments fell 64.97% year-over-year to $11.8 million in Q2 2023, while the trailing twelve-month figure through Mar 2024 was $11.8 million (down 89.08% YoY) and the FY2023 annual result came in at $23.0 million, down 83.64% from the prior year.
• Change in Acquisitions & Divestments climbed to $11.8 million in Q2 2023 per MCRB's latest filing, from $11.2 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $54.8 million in Q2 2021 and troughed at $2.5 million in Q3 2020.
• A 5-year average of $27.3 million and a median of $22.4 million in 2020 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2021 and 2023: Change in Acquisitions & Divestments surged 1653.98% in 2021, then plunged 74.52% in 2023.
• Over 5 years, Change in Acquisitions & Divestments stood at $16.9 million in 2019, then climbed by 1.68% to $17.2 million in 2020, then jumped by 154.03% to $43.6 million in 2021, then plunged by 50.81% to $21.5 million in 2022, then slumped by 45.27% to $11.8 million in 2023.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $11.8 million, $11.2 million, and $21.5 million for Q2 2023, Q1 2023, and Q4 2022 respectively.